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Treatment option for Chronic Kidney Disease-Stage5 (CKD-stage5) 
patients fall into three categories viz., Haemodialysis, Peritoneal dialysis and 
Renal Transplantation.  Many studies proved that the kidney transplantation is 
distinctly superior and it is associated with reduced mortality and morbidity 
compared to haemodialysis or peritoneal dialysis3 – 16.  
The renal donors are of three types viz. live related, live unrelated and 
cadaver.  With nuclear families, working members in the family and the increased 
prevalence of diabetes mellitus and hypertension among general population, it is 
difficult for the CKD-stage5 patients to get suitable willing live donors.  The only 
























   
 
 
                
  
















































































 REVIEW OF THE LITERATURE 
 The most clinically useful method of assessing renal transplantation 
outcomes is measurement of allograft survival.  Other important measures include 
allograft function (typically measured by serum creatinine), patient survival, 
number and severity of acute rejection episodes, days of hospitalization, and 
quality of life indices.  Most of the data for assessing transplant outcome is from 
United States Renal Database System (USRDS)1, Collaborative Transplant Study 
(CTS)2 and Australia and New Zealand Dialysis and Transplant (ANZDATA) 
Registry.   
Actual and Actuarial Allograft and Patient Survival     
 Allograft survival is calculated from the day of transplantation to the day of 
reaching a defined endpoint (i.e., return to dialysis, retransplantation, or death, 
whichever occurs first).  In practice, survival is usually calculated by actuarial 
methods.  These methods imply estimation or projection of survival since not all 
patients will have been followed for the same period of time.  Also, since not all 
patients will have reached the defined endpoint, censoring of such patients is 
required.  Projected survival estimates must be interpreted with caution; projected 
survival may ultimately not be as impressive as actual survival11.  Another 
actuarial measure commonly used is graft half life.  Graft half life is the number 
of years before 50% of the graft, that survive at one year will fail or the patient 
will die with a functioning graft.   
 
  Traditionally, graft survival is assessed under two distinct time phases: 
early and late.  Early graft loss refers to loss in the first 12 months and late loss to 
any time thereafter.  In the first 12 months, graft loss is not rare because of 
technical complications such as graft thrombosis and severe rejection.  After 12 
months, the incidence of graft loss is lower but remains quite stable over time.  
Usually, analysis of long term survival is restricted to those allografts that have 
survived to 12 months post-transplantation.  By this definition, patient death is 
equivalent to graft loss.  Graft survival can also be calculated after censoring for 
patient death.  Death with a functioning allograft is not necessarily a bad outcome 
and in fact is probably the best outcome, provided survival after transplantation is 
prolonged.     
SHORT TERM OUTCOMES IN RENAL TRANSPLANTATION    
 The principal causes of graft loss in the first post-transplantation year are 
acute rejection, graft vessel thrombosis, primary nonfunction, sepsis and patient 
death.  The current adjusted one year survival probability for recipients of 
deceased donor allografts (first or subsequent transplant) is 91%; this has slowly 
but steadily improved over the past 25 years.  The principal causes of patient 
death in the first year are cardiovascular disease and infection.    
LONG TERM OUTCOMES IN RENAL TRANSPLANTATION    
 There has also been a steady improvement in long term allograft survival.  
Recently this increase has occurred mainly in higher risk patients, such as those 
undergoing retransplantation.  Beyond the first post-transplantation year, the 
principal causes of renal allograft loss are patient death and chronic allograft 
 nephropathy; less common causes are late acute rejection and recurrent disease8.  
Chronic allograft nephropathy is a nonspecific term and in practice often 
encompasses chronic damage due to ischemia, rejection and calcineurin inhibitor 
toxicity.  The number one cause of death post-transplantation remains 
cardiovascular disease, followed by infection and malignancy.  In children, 
however, death is a much less common cause of graft loss; conversely, in the 
elderly, it is more common. 
FACTORS AFFECTING RENAL ALLOGRAFT SURVIVAL 
 Prospective studies and analyses of registry data have shown that many 
factors are associated with renal allograft survival.  These can be considered as 
either donor, recipient, or donor-recipient.   
Donor-Recipient Factors 
Delayed Graft Function 
 Delayed graft function (DGF) is usually defined as failure of the renal 
allograft to function immediately post-transplantation, with the need for one or 
more dialysis sessions within a specified period, usually one week.  DGF is 
associated with poorer graft survival, poorer graft function, and higher risk of 
patient death10, in part because of the association of DGF with higher rates of 
acute rejection.  Rejection may be more common because ischemia-reperfusion 
injury increases the immunogenicity of the graft.  Most studies have also 
demonstrated that, even in the absence of documented acute rejection, DGF is 
associated with poorer long term graft function and survival11.   
  Risk factors for DGF are: 
¾ Donor age (>40 years) 
¾ Cold ischemia time (>12 hrs) 
¾ Recipient race  
¾ PRA (>50%) 
¾ HLA mismatch  
¾ Duration of dialysis 
HLA Matching 
 Registry data from many countries clearly demonstrate that, even with 
current immunosuppression regimens, better HLA matched deceased donor 
allografts still have better survival18.  This is why many countries operate national 
or international sharing systems for zero-mismatched renal allografts, even though 
this prolongs cold ischemia times.  The hazard ratio of graft failure for recipients 
of a zero-mismatched allograft in the 1998 to 2003 cohort was 0.85 (0.78 to 0.92) 
compared to 1.24 (1.15 to 1.34) for recipients of a three mismatched allograft1.  
The better outcomes are presumably related to fewer immunologic failures.  There 
is some evidence, however, that the benefits of HLA matching are diminishing, 
probably because of more effective immunosuppression18.  
Cytomegalovirus Status of Donor and Recipient 
 Registry data show a small but definite effect of donor and recipient 
cytomegalovirus (CMV) serologic status on renal allograft and recipient survival1. 
 Donor negative-recipient negative-pairing have the best outcomes, whereas donor 
positive-recipient negative pairing have the worst.  CMV probably affects graft 
outcomes via overt infection, but subclinical effects on immune function may also 
be important.    
Center Effect 
 Not surprisingly, outcomes have varied widely among transplantation 
centers.  This reflects normal statistical variance as well as center expertise.  It is 
important to note that outcomes will be confounded by many donor and recipient 
factors that differ across centers.  Thus, between center comparisons are difficult.  
USRDS data suggest minimal difference in outcomes between small and large 
transplantation centers in the United States45. 
Donor Factors 
 The quality of the kidney immediately prior to transplantation has a major 
impact on long term graft function and the risk of developing chronic allograft 
nephropathy. 
Donor Source : Deceased versus Living Donor 
 The donor source is one of the most important predictors of short and long 
term graft outcomes.  In general, living donor grafts are superior to deceased 
donor grafts.  The better healthy living donors, the absence of brain death, the 
general benefits of elective as opposed to semi emergency surgery, avoidance of 
ischemia-reperfusion injury, high nephron mass and probably the effects of a 
 shorter waiting time.  Better compliance by the recipient in view of the 
relationship e.g., spouse, a care giver may also play a role.   
Donor Age 
 Deceased donor and living donor allografts from those aged older than 50 
years, and particularly older than 65 years, have poorer outcomes1.  These results 
are thought to reflect a higher incidence of DGF and of “nephron underdosing”.  
Grafts from older donors have fewer functioning nephrons because of the aging 
process and donor-related conditions such as hypertension and atherosclerosis.   
Cold Ischemia Time 
 Prolonged cold ischemia time is associated with higher risk of DGF and 
poorer allograft survival19.  Registry data suggest that >24 hours is particularly 
deleterious to the graft1. 
Donor Race 
 The survival of deceased donor grafts obtained from African-Americans is 
poorer than grafts from Caucasians.  One theory is that a lower nephron number in 
African Americans is important. 
Donor Sex 
 There is evidence that grafts from deceased females donors have slightly 
poorer survival, particularly in male recipients1,20.  This probably reflects 
“nephron underdosing”, as females have smaller renal mass than males.  
However, differences in the antigenicity of female grafts may also be a factor19. 
 Donor Nephron Mass 
 An imbalance between the metabolic/excretory demands of the recipient 
and the functional transplant mass has been postulated to play a causative role in 
the development and progression of chronic allograft nephropathy.  “Nephron 
underdosing”, exacerbated by perioperative ischemic damage and postoperative 
nephrotoxic drugs, might lead to nephron overwork and eventual failure, similar 
to the mechanisms occurring in native kidney disease.   
Expanded Criteria Donors 
 As the discrepancy between the number of patients awaiting kidney 
transplantation and the number of available organs increases, many countries are 
now using expanded criteria donor (ECD) allografts21 previously named marginal 
kidney donor.  ECD kidney is defined as a kidney from a deceased donor older 
than 60 years or aged 50 – 59 years with two additional risk factors including a 
history of hypertension, death due to CVA or elevated creatinine (>1.5 mg/dl).  
Survival of ECD kidneys is, on average, shorter than regular deceased donor 
kidneys for two general reasons : first, the baseline GFR of these kidneys is likely 
to be lower and, second, ECD kidneys tend to be transplanted into older recipients 
who have higher rates of post-transplantation death.  However, it should be 
emphasized that transplantation with an ECD kidney always confers a significant 
survival advantage compared to remaining on the transplant waiting list (on 
dialysis for long)10. 
 
  Other nontraditional donors are non-heart beating donors.  The use of non-
heart beating donors has been controversial as short term outcomes are inferior to 
those seen with standard deceased donor kidneys.  This reflects the longer period 
of warm ischemia.  Rates of DGF and primary nonfunction are generally higher 
than with standard donors.   
Recipient Factors 
Recipient Age  
 In general, graft survival rates are poorer in those at the extremes of age: 
younger than 17 and older than 65 years1.  In the young, technical causes of graft 
loss such as vessel thrombosis are relatively more common.  Acute rejection is 
also a more common cause of graft loss; conversely, death with a functioning 
graft is relatively rare. 
 The elderly (those older than 65 years) are forming an increasing 
percentage of the incident and prevalent Chronic Kidney Disease-stage5 
population.  Many of these patients have significant comorbid disease, particularly 
cardiovascular disease and type 2 diabetes mellitus.  Nevertheless, age per se is 
not a contraindication to transplantation: among elderly patients carefully 
screened and deemed fit for the procedure, long term outcomes are clearly better 
with transplantation than dialysis3.  It is, therefore, appropriate that transplantation 
in elderly recipients is becoming more common compared with younger 
recipients, death with a functioning graft is a more common cause of graft loss in 
the elderly (responsible for >50% of graft failures).  Conversely, acute rejection 
may be less common.  Thus, although randomized, controlled trials are not 
 available, it seems reasonable, in general, to use less aggressive 
immunosuppression in the elderly.   
Recipient Race 
 African American recipients have poorer deceased donor graft survival 
compared to Caucasians1.  This probably reflects multiple factors including higher 
incidence of DGF, higher incidence of acute and late acute rejection, stronger 
immune responsiveness, a predominantly Caucasian donor pool (with resultant 
poorer matching of HLA and non-HLA antigens), altered pharmacokinetics of 
immunosuppressive drugs, and a higher prevalence of hypertension.  
Socioeconomic factors associated with inability to pay for transplant medications, 
poorer access to high-quality medical care and noncompliance probably also play 
an important role.   
Recipient Gender 
 Registry studies of the association of recipient gender with transplantation 
outcomes have yielded differing results.  In the CTS database2, female recipients 
had slightly better allograft survival than male recipients of deceased donor 
kidneys or HLA identical kidney20.  An important difference between female and 
male transplantation candidates is the higher degree of sensitization of the former 
to HLA antigens and possible non-HLA antigens.  Females tend to be more 
sensitized because of pregnancy and possible because of more blood transfusions 
related to menstruation. 
 
 Recipient Sensitization : before or after Transplantation 
 Patients who are broadly sensitized (e.g., panel reactive antibody [PRA] 
status >50%) at the time of transplantation generally have poorer early and late 
graft survival compared to nonsensitized recipients.  This is mainly related to an 
increased incidence of complications in the early post-transplantation period such 
as DGF and acute rejection.  The principal reasons for sensitization are previous 
transplants, pregnancy, and previous blood transfusions.  Highly sensitized 
patients are often given more intensive immunosuppression to reduce the risk of 
rejection, but this also exposes them to risk of infection and malignancy. 
 There is accumulating evidence that the presence of donor specific and 
nondonor specific HLA antibodies are associated with inferior graft survival21.  
This evidence suggests that low grade antibody mediated rejection is an important 
cause of graft damage. 
Recipient HCV Antibody and HBsAg  
 Recipients who are hepatitis C virus (HCV) antibody positive at the time of 
transplantation have poorer allograft survival and poorer survival1,23.  Higher 
mortality rates appear to be related to infection and worsening liver disease23.  
Nevertheless, it seems that transplantation of selected HCV positive patients 
confers a survival benefit as opposed to remaining on the dialysis26.   
 
 
  The adverse effects of hepatitis B virus (HBV) surface antigen positivity 
on post-transplantation outcomes are much less pronounced.  This may in part 
reflect the better anti-HBV therapies available for transplant recipients that have 
been introduced in recent years. 
Acute Rejection 
 Acute rejection has been consistently associated with an increased risk of 
graft loss.  This is due to irreversible graft injury at the time of acute rejection and 
probably ongoing subclinical immunemediated injury.  Such damage accentuates 
the effects of poor quality donor tissue, preoperative ischemic injury, nephron 
underdosing, and so forth.  Acute rejection refractory to steroids, acute rejection 
where creatinine does not return near baseline, and late acute rejection (occurring 
after the first 6 months) are particularly associated with poorer graft and patient 
outcomes17.  More severe histologic changes (e.g., Banff grade II or III cellular 
rejection) or severe acute antibody-mediated rejection are also associated with 
poorer graft survival.  Although current immunosuppressive regimens have 
steadily decreased rates of acute rejection, this has not necessarily translated into a 
major improvement in long term graft survival.      
Recipient Immunosuppression 
 Undoubtedly, the improvements in short and long term allograft survival 
reflect, in part, the effectiveness of the newer antirejection, drugs such as the 
cyclosporine, tacrolimus and mycophenolate mofetil.  The short term 
improvements in allograft survival have been particularly impressive.  The 
contribution of long term CNI therapy, particularly with currently used 
 maintenance doses, to chronic renal allograft dysfunction (and loss) remains 
controversial.  The increases in short and long term graft survival in the CNI era 
(cyclosporine became widely used in the early 1980s) suggest that these 
antirejection effects override the nephrotoxic effects.  Tacrolimus was more 
effective than cyclosporine in preventing acute rejection and allograft loss but at 
the expense of higher rates of diabetes mellitus28. 
 There is limited evidence (registry data, not randomized trials) that 
mycophenolate mofetil improves long-term graft survival both by preventing 
overt acute rejection and possible by other mechanisms.  Significant level of 
cyclosporine and tacrolimus produces 30% increase in bioavailability of 
mycophenalate mofetil.  Short term studies of sirolimus have shown contradictory 
results29,30.  In fact, one registry study suggests that sirolimus use is associated 
with inferior allograft survival31. 
 Although antilymphocyte antibody preparations (e.g., antithymocyte 
globulin or interleukin-2 receptor blockers) are often used, particularly in the 
setting of DGF, their effects on long term graft survival have not been well 
studied.  Recent United Network of Organ sharing data suggest that antibody 
induction protocols slightly reduce early acute rejection episodes in recipients 
with DGF and slightly improve graft survival.  It is important to note that 
aggressive immunosuppression could adversely affect graft survival by promoting 
BK (polyoma) virus nephropathy or higher rates of death from opportunistic 
infections. 
 
 Recipient Compliance 
 Poor compliance with the immunosuppressive regimen is known to 
increase the risk of acute rejection, particularly late acute rejection, and chronic 
allograft dysfunction.  The magnitude of this problem is difficult to define.  In one 
study of patients followed up to 5 years after transplantation, 22.6% were 
identified as being noncompliant; this was associated with a large increased in risk 
of late acute rejection and of higher plasma creatinine32. 
Obesity 
 Obesity is increasingly common in Chronic Kidney Diseae-stage5 patients 
and is associated with more transplantation surgey-related complications, more 
DGF, higher mortality (related to cardiovascular complications), and poorer graft 
survival33.  Similar evidence of poorer patients and graft outcomes has been 
reported by USDRS1.  The poorer long term graft survival probably reflects the 
effects of DGF, nephron overwork, and more difficult dosing of 
immunosuppressive drugs.  Nevertheless, most studies of patients with BMI >30 
kg/m2 suggest transplantation provides a survival benefit over remaining on the 
waiting list (on dialysis) at least up to a BMI of 41 kg/m2. 
Recipient Hypertension : Angiotensin system 
 Retrospective studies have shown that the greater the severity of post-
transplantation hypertension is, the higher is the risk of graft loss34.  Of course, 
hypertension could also be secondary to graft damage and not just a cause.  No 
prospective human studies of the effect of treating hypertension on allograft 
 outcomes are available.  However, control of hypertension is associated with 
improved allograft survival35. 
 Multiple studies have confirmed the ability of angiotensin converting 
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to slow the 
progression of both diabetic and nondiabetic proteinuric native kidney disease.  
ACE inhibitors and ARBs should be similarly beneficial in transplant kidney 
disease and thus should be used more frequently.  While several studies have 
shown that both classes of drugs are effective in treating post-transplantation 
hypertension and reducing proteinuria in the short term, no long term studies of 
their effects on progression of transplant kidney dysfunction have been published.  
In one randomized, controlled trial, patients randomized to nifedipine had 
sustained improvement in GFR up to 2 years after transplantation; no 
improvement was seen in the lisinopril group.  This may reflect the ability of 
nifedipine to attenuate CNI-induced vasoconstriction of the afferent arteriole33. 
Recipient Dyslipidemia 
 The prominence of the vascular lesions in CAN and the similarity of these 
lesions to atherosclerosis suggest that dyslipidemia plays a role in the 
pathogenesis of CAN and graft failure.  Some studies have suggested that 
hypercholesterolemia and/or hypertriglyceridemia are associated with porer graft 
outcomes.   
 
 
 Recurrence of Primary Disease 
 Determining the incidence and prevalence of recurrent or de novo renal 
disease is difficult.  The original cause of Chronic Kidney Diseae-stage5 is often 
unknown; most relevant studies are small and retrospective with variable follow-
up periods.  In one of the best performed studies of transplant recipients whose 
cause of Chronic Kidney Disease-5 was glomerulonephritis, the cumulative 
incidence of graft loss at 10 years was 8.4%36.  Recurrence was the most 
important cause of loss, after chronic rejection and death.  It is likely that a renal 
allograft survival continues to improve, recurrent or de novo disease will be 
increasingly diagnosed (both clinically and histologically) and will become a 
more important cause of late graft loss.   
Proteinuria 
 The degree of proteinuria correlates with poorer renal outcome in both 
native and transplant kidney disease.  Proteinuria may simply be a marker of renal 
damage, but there is speculation that proteinuria per se may accelerate allograft 
loss from CAN.   ACE inhibitors and ARBs has definite role in showing the 
progression of proteinuria transplant renal disease.   
Measures to improve renal allograft survival 
 Increased living kidney donation : both related and nonrelated. 
 Preemptive transplantation in live kidney transplantation. 
 Increased donation from younger, previously healthy deceased donors. 
  Preferential matching of younger deceased donors with younger 
recipients. 
 Zero mismatching of HLA antigens 
 Improved organ preservation 
 Reduced cold ischemia time 
 Nephron dosing (e.g. matching of donor recipient sex, body mass 
index) 
 Calcineurin inhibitor sparing immunosuppressive protocols. 
 Angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers. 





















                           
 
















 MATERIALS AND METHODS 
Study place   : Stanley Medical College 
     Nephrology Department, Chennai 
Study period  : From October 2008 to April 2010 
Study design  : Prospective study 
Study population  : All 24 consecutive patients who underwent  
     Cadaver transplant in this period were enrolled. 
CRITERIA FOR TAKING UP FOR CADAVER TRANSPLANT:  
¾ Patients in cadaver waiting list 
¾ Patients with irreversible renal failure 
¾ Dialysis dependent patients 
¾ Patients under the age of 50 years 
¾ Second Transplant patients 
¾ ABO compatible patients 
EXCLUSION CRITERIA: 
¾ All Live related donor transplant and spousal transplant. 
¾ Multi organ transplant 
¾ Expanded criteria donor 
¾ Non heart beating donor transplant 
¾ Diabetic patients 
¾ Patients with severe co-morbid conditions 
¾ Patients with peripheral vascular disease 
 
  Recipients demographic factors like Age, Gender, Occupation, Literacy 
were noted. 
 Selection of recipients is based on their seniority in cadaver waiting list and 
cross match result. 
 All recipients were maintained on Haemodialysis. 
 All recipients were ABO compatible and cross-match negative and they are 
followed up regularly in our OP.  
 Human Leukocyte Antigen (HLA) and Panel Reactive Antibody (PRA) 
were not done to any of our recipients.   
 CMV status of the recipient was not checked routinely.  However, if any 
suspicion of CMV infection like hepatitis, leucopenia, etc., the CMV status 
of the recipient was checked with pp65 antigen and treated with 
Vangancyclovir if they were positive.     
 Graft survival was the primary outcome analysed. 
 There were no drop outs from follow-up. 
 Donor kidneys were received from various hospitals in Tamil Nadu and 
from our own hospital.  
 Donors age ranged from 15 – 60 years without evidence of kidney disease 
or any infection. 
 None of donors had diabetes mellitus or hypertension. 
 All the donors had negative serology (HBV, HCV, HIV). 
  All grafts were perfused with HTK solution (Custodial solution) 
 Custodial (HTK) solution (in mmol/L) 
• Sodium chloride    15.0 
• Potassium chloride      9.0 
• Potassium hydrogen 2-ketoglutarate   1.0 
• Magnesium chloride     4.0 
• Histidine Hcl        18.0 
• Histidine             180.0 
• Tryptophan       2.0 
• Mannitol     30.0 
• Calcium chloride             0.015 
 They are stored in ice box with three bag technique during transportation 
 Donor’s age, sex, cause of death, graft side and abnormality and 
biochemical profile were noted. 
 Transplant surgery was done by two teams of Urologists. 
 Ethical Committee approval from Stanley Medical College, Chennai was 
obtained for this study.  
DECEASED DONOR GRAFT ALLOCATION POLICY 
 
A separate cadaver waiting list for each blood group of potential recipients 
is maintained according to their date of induction into haemodialysis.  This 
seniority list is available online and it is supervised by transplant committee 
formed by the Government of Tamil Nadu. 
Recipients with co–morbid conditions are temporarily deleted from the list 
and included again once they recover. 
 
 PROCEDURE 
Pre operative treatment 
 All recipients were given Haemodialysis pre operatively.  They were 
started on immunosuppression prior to surgery as below. 
 Day before Surgery 4 p.m. 0 POD (4 a.m.) 
T.Tacrolimus 0.066 mg/kg 0.066 mg/kg 
T.MMF 500 mg 500 mg 
T.Prednisolone 0.5 mg/kg 0.5 mg/kg 
  
Operative Technique 
 Grafts are placed in the right iliac fossa after creating renal bed except in 
second transplant.  Anastomosis of the renal vessels to the iliac vessels was 
performed as follows. 
Graft artery to internal iliac artery (except one patient) – end to end.   
Graft vein to external iliac vein – end to side.   
Ureter anastomose to bladder obliquely in the region of the trigone.  DJ stents 
were applied if required. 
 During anastomosis of graft vessels, methyl prednosolone 1 g was given as 
I.V. infusion. 
Post operative treatment 
 Fluids (0.9% NS) were given according to their urine output.  
Immunosuppression was given as follows: 
  T.Tacrolimus 0.066 mg/kg Bd (Target tacro level 10 – 12 ng/ml 
subsequently reduced to 5ng/ml by 6 months) 
 T.MMF 500 mg Bd 
 T.Prednisolone 0.5 mg od 
 Tacrolimus levels were assessed on POD-5 for all recipients.  Doppler of 
graft vessels are assessed on POD-7.  Recipients urinary Foley’s Catheter was 
removed on     POD-7.  Drainage tube was removed if drainage fluid is less than 
50 ml.  DJ stent was removed on 4th post operative week. 
 After 10 days, recipients were discharged and they were seen as outpatient 
at intervals of twice weekly for one month than weekly once for two months, 
thereafter fortnightly for one year and monthly for one year life long.  During 
each visit, patient’s condition, renal function test and complete blood count were 
analyzed.  Post operative drugs including immunosuppressants are given free of 










 STATISTICAL METHODOLOGY 
 
 
The statistical analysis has been done by using SPSS (Statistical Package 
on Social Science) version 10.0 has been used.  
The non-parametric model can be used to find out the relationship of 
categorical variable.  One of the methods is Fisher’s exact Chi-square. It can be 
used when the cell counts are less than five.  Here for all the tables the cell value 
is less than five.  Hence it has been used. 
To find out the relation of Graft function with other risk factors like age, 
gender, creatinine in one month, creatinine in 6 month, dialysis duration, LVH, 
Intra operative status, Postoperative status, CIT, and Transplant order, the above 
method has been used. 
The factors like age, BMI, creatinine in one month, creatinine in six 
months, has been classified or categorized into two groups according to their 
mean or average. The other factors like dialysis duration and Cold Ischemia Time 










































24 patients received cadaver graft in our center from October 2008 to April 
2010.  Mean age of the recipients was 33.8 years (±SD 7.17).  Among them males 
were 20(83%) and female were 4(17%).  
Out of 24 patients one had ADPKD, one had biopsy proven IgA 
nephropathy and the remaining had contracted kidney for which native kidney 
biopsy was not done. The cause of chronic kidney disease for them is not known. 
During the period of study, Diabetic patients were not included in the 
cadaver waiting list. All recipients were on antihypertensives.  One of the 
recipients was Hepatitis B positive. One was Hepatitis C positive.  None of the 
patients received induction therapy like ATG (Anti thymocyte globulin), 
Daclizumab or Basiliximab. 
Among the recipients 20(83.3%) were males and 4(16.7%) were females. 
Only one recipient had second transplant and all other had first transplant. One 
patient had ADPKD, one patient had biopsy proven IgA nephropathy and all other 
had unknown etiology. All of them had normal renal and iliac vessels         
(doppler done pre operatively). All the recipients received tacrolimus, 
mycophenolate mofetil and prednisolone 
Among the recipients 8 were of Blood group  O positive(33.3%), 10 were 
B positive(41.7%), 3 were AB positive(12.55%), one each of A positive(4.2%), A 
negative(4.2%) and B negative(4.2%).  
 
 
 Average age of the donors was 32.3 years (±SD14.32%).  Among them 
males were 16(66.7%) females were 8 (33.3%). 3 (12.6%)donors  had fall from 
height as the cause of brain death. Others were due to road traffic accident. 
Among the donors 9(37.55) were O positive 10(41.7%) were B positive, 
3(12.5%) were A positive, 2(8.3%) were AB positive. 
Among the received grafts 17(70.8%) were left sided graft, 7(29.2%) were 
right sided graft. 17(70.8%) graft were without any vessel or ureteric anomalies.  
Among remaining grafts 4(16.7%) had 2 renal arteries, 1 (4.2%) had 2 renal veins, 
2(8.4%) had 3 renal arteries. All the grafts were perfused with HTK (custodial) 
solution.  
Out of total 24 recipients, 9(37.5%) had DGF, 8(33.3%) died and one had 
graft nephrectomy . 
Intraoperatively, 17(70.8%) recipients did not have any intraoperative 
events, one (4.2%) recipient had bleeding from renal bed, two (8.3%) had 
hypotension during surgery, one (4.2%) had on the table mottling of graft after 
clamp release and one (4.2%)  had graft artery anastomized close to the hilum. 
Postoperatively, two (8.4%) recipients had sepsis and one (4.2%) had 
culture proven fungal sinusitis, one (4.2%) had pancreatitis, one (4.2%) had 
biopsy proven ATN and one (4.2%)  had ischemic necrosis of the right leg. 
The influence of various demographic, biochemical and clinical parameters 
of recipients and donors in influencing graft function are analyzed.  
 Only two factors are statistically significant to influence the graft function. 
Cold ischemic time significantly influenced the graft function and creatinine at 


















































Transplant failure represents a current challenge in nephrology. In this 
study prolonged cold ischemic time was found to affect graft survival 
significantly. One month creatinine value predicted patient’s survival. DGF 
occured among 37.5% of deceased graft recipients.  Compared to western studies 
(90%), patient survival was 66.7% and graft survival was 62.5% only. This may 
be because of the learning curve in cadaver transplants in spite of around 40 live 
transplants being done every year.  Difficulty in deceased donor graft 
procurement, transportation of graft, delay in getting cross match results 
especially during odd hours and different transplant surgeons contributed to the 
poor graft survival. Over a period of time these are bound to improve. 
In this study the prolonged cold ischemic time is mainly attributed to 
transplant being performed the following day, when the graft is received at odd 
hours. 
Infection was found to be the prime cause of death in deceased donor graft 
recipients.  Out of 8 deaths, 3 were due to sepsis, one each due to biopsy proven 
acute rejection, HUS and CAN.  
The graft survival was not significantly influenced by recipient’s age, 
gender, dialysis duration, intra-operative hypotension, post – operative sepsis and 
their serology status.  The number of cadaver transplants may not be sufficient to 
discern statistically significant trend.  
 
 
 THE CLINICAL COURSE OF PATIENTS WHO EXPIRED AND A 
PATIENT WHO UNDERWENT GRAFT NEPHRECTOMY 
 
CASE 1: Kondia Raj 
Male aged 36 years presented with uremia and contracted kidneys. During 
the surgery the renal graft was found to have triple renal artery with Carrel aortic 
patch.  He had a uneventful post operative period.  But later he developed graft 
dysfunction after 15 months. Graft biopsy showed CAN. Then he become dialysis 
dependant and died at his native palace. 
CASE 2: Bala Raman 
Male, aged 32 years had been uremic for one year. He had uneventful 
intraoperative and postoperative period. He was maintaining normal graft function 
for almost one year post transplant. Then he developed acute hepatitis due to HCV 
virus and hepatic encephalopathy from which he did not recover and died. 
CASE 3: Sasi Kumar 
Male aged 29 years, a case of CKD stage-5 of unknown etiology on 
maintenance haemodialysis for two years.  He had uneventful intraoperative and 
postoperative period.  He was maintaining normal graft function for three months. 
Then he developed CMV pneumonia and died with normal graft function.   
CASE 4 : Dasan  
Male aged 48 years, a known case of ADPKD and positive serology for 
hepatitis B virus on maintenance haemodialysis for two years. He had uneventful 
intraoperative period and he developed fever postoperatively on 14th day from 
which he recovered with antibiotic.  He developed DGF post operatively and 
 dialyzed eight times.  His discharge creatinine was 2.4.  After three months he 
developed bronchopneumonia, sepsis and respiratory failure.  He was on 
ventilator for one day and died. 
CASE 5 : Xavier 
Male aged 43 years on maintenance haemodialysis for two years received 
deceased donor graft with two renal arteries. Main renal artery anastomosed to 
internal iliac artery and accessory artery to external iliac artery. Following clamp 
release, his right leg pulse was not palpable.  He was reexplored and no thrombus 
was found.  The graft was reanastomosed. Next day patient developed ischemic 
necrosis of right leg due to femoral artery thrombus for which he underwent 
femoro femoral bypass.  The same day he expired due to sepsis and arrhythmia. 
CASE 6 : Basker 
Male aged 38 years, a case of CKD of unknown etiology on maintenance   
haemodialysis for three months. He had uneventful intraoperative and 
postoperative period and he was maintaining normal graft function for 4 month 
post transplant.  Then he developed graft dysfunction and returned to dialysis. 
Graft biopsy showed features of HUS.  Subsequently, he became HCV positive 
and died in outside hospital. 
CASE 7 : Eswaran 
Male aged 31 years on maintenance haemodialysis for one year. He 
underwent second transplant and he had persistent hypotension intraoperatively. 
He returned to dialysis due to DGF.  He had persistent blood stained drainage in 
DT for which he was reexplored and blood clots found around graft which was 
 evacuated and graft found to be normal.  Open graft biopsy done showed features 
of both acute humoral and cellular rejection.  He was not treated for that as he had 
persistent fever then he developed pain over graft site and graft swelling. Graft 
nephrectomy done following which patient expired due to sepsis. 
CASE 8 : Rajan 
Male aged 36 years on maintenance haemodialysis for three months had 
uneventful transplantation.  He was returned to dialysis due to DGF and found to 
have fungal sinusitis and a palate swelling.  Culture of palate lesion grew mixed 
organism of herpes, Candida and mucor. Then he developed CNS infection and 
died. 
CASE 9 : Sakthivel 
Male aged 22 years on maintenance haemodialysis for three year.  He is a 
known case of hepatitis C positive.  During surgery after clamp release graft 
become mottled on table.  After 30 minutes kidney become pink and abdomen 
closed. Postoperatively he developed DGF and returned to dialysis. Two weeks 
later he developed hypotension and abdomen swelling.  He was taken up for graft 
nephrectomy.  He was found to have graft rupture.  Graft biopsy showed features 







TABLE - 1 
BASELINE CHARACTERISTICS OF RECIPIENTS 
 





Male 20 83.3 
Female 4 16.7 






O positive 8 33.3 
B positive 10 41.7 
A positive 1 4.2 
AB positive 3 12.5 
B Negative 1 4.2 




ADPKD 1 4.2 
Unknown cause 22 91.7 
IgA N 1 4.2 




Left 17 70.8 
Right 7 29.2 




I 23 95.8 
II 1 4.1 
8 ECHO 10 41.7 
9 Immunosuppression 






















 TABLE- 2  
BASELINE CHARACTERISTICS OF DONOR 
 




Male 16 66.7 





O positive  9 37.5 
B  positive 10 41.7 
A  positive 3 12.5 
AB positive 2 8.3 
 
3 
Cause of Death 
RTA 21 87.5 










 TABLE 3 
PATIENT SURVIVAL 
 
Outcome Frequency Percentage 
Death 8 33.3 























Outcome Frequency Percentage 
DGF 9 37.5 





























No Intra Operative Events Frequency Percentage 
1. Bleeding from renal bed 1 4.2 
2. External Iliac – Anastamosis 1 4.2 
3. Hilum – Anastamosis  1 4.2 
4. Hypotension  2 8.3 
5. Mottling 1 4.2 
6. Uneventful  17 70.8 
















POST OPERATIVE EVENTS 0 TO 14 DAYS 
 
No. Post Operative Events Frequency Percentage 
1. Accelerated hypertension  1 4.2 
2 Biopsy proven ATN 1 4.2 
3 Fungal Sinusitis   1 4.2 
4 Hypotension  1 4.2 
5 Ionotropic requirement   1 4.2 
6 Nephrectomy  1 4.2 
7 Nil Events  11 45.8 
8 Pancreatits  1 4.2 
9 Right Leg Ischemia  1 4.2 
10 Sepsis 2 8.3 

















Variable No DGF DGF TOTAL P Value 
Age
Age<34 10 4 14 
0.403 
Age>34 5 5 10 
Sex 
Male 14 8 22 
0.620 
Female 1 1 2 
BMI 
<21.5 9 4 13 0.390 
>21.5 6 5 11 
Tx I/II 
I Tx 15 8 23 
0.375 
II Tx 0 1 1 
LVH 
No LVH 9 5 14 
1.00 
LVH 6 4 10 
HD-Duration 
<18mon 9 4 13 
0.374 
>18mon 6 5 11 
HBV/HCV 
NEGATIVE 15 7 22 
0.673 





















































   
Variable No DGF DGF total P Value 
Age 
<34 10 4 14  
0.345 
>34 5 5 10 
Gender 
Male 10 7 17  
0.669 














INTRA OPERATIVE FACTORS 
 
 
Variable No DGF DGF TOTAL P Value 
Hypotension 
YES 15 7 22  
0.130 NO 0 2 2 
CIT 
<8 Hrs 7 0 7  
>8 Hrs 8 9 17 0.020Ë 













Variable No DGF DGF total P Value 
Sepsis 
Absent 14 8 22 
0.100 
Present 2 1 3 
Cr-1 mon 
<1.3 11 2 13 
0.045Ë 
>1.3 3 3 6 
Cr-6 mon 
<1.1 9 1 10 
0.118 





































Factors Died Live P.value 
Recipient Age 
>34 4 10 0.673 
<34 4 6 
Gender 
Male 8 14 0.435 
Female 8 2 
Dialysis duration 
< 18 mon 4 9 0.556 
> 18 mon 4 7 
BMI 
< 21.5 3 10 0.675 
>21.5 5 6 
Serology 
Neg 7 15 0.130 
HBV/HCV + 1 1 
Sepsis 
Present 13 8 0.100 
Absent 1 2 
CIT 
< 8 HRS 2 5 0.076 
> HRS 6 11 
DONOR AGE 
< 34 4 10 0.403 

























¾ Cadaver transplantation is the need of the day and is bound to increase 
with lesser number of live related transplants.   
¾ Optimal HLA mismatching between recipient and donor is not being 
performed in India. 
¾ Cadaver transplant with increasing experience have more successful 
outcome. 
¾ Reduction in cold ischemic time by sharing the organ within the City, 
availability of emergency cross-match facility and performing 
transplant surgery without delay will improve the graft survival. 
¾ Use of induction therapy might avert early graft failures. 
¾ Patients with CKD Stage-5 on maintenance haemodialysis without 
voluntary live related donor will benefit immensely by cadaver 
transplantation. 
¾ In our study, three patients died due to sepsis.  Early detection of 
sepsis, aggressive treatment and possibly regular checking up of CMV 
status could improve graft outcome in medium term. 
¾ One patient was lost due to surgical cause which would improve with 
further experience. 
¾ One patient died of early sepsis and fungal infection.  Source of 
infection could have been from cadaver. 
¾ Induction therapy might have averted immediate rejection and graft 
rupture which occurred in one patient in our study. 
 ¾ Early detection and aggressive treatment of CMV infection which 
would avert the graft loss in one of our patients.  
¾ One patient with HCV developed sepsis and died.  For him HCV was 
not treated. 
¾ To conclude, cadaver transplant is a challenge and the results would 
improve with attacking multiple causes of graft failure. 
¾ Avoiding HCV infection during dialysis, gaining more experience in 
transplant surgery, surveillance of infection from cadaver donor, 
induction therapy, regular CMV surveillance, early detection and 
treatment of sepsis should go a long way in improving the results. 
¾ In addition, the ideal of sharing HLA matched kidney across the State 
or India remains a distant dream.   
¾ In the absence of such HLA based sharing, more declaration of brain 
death in our own centre, immediate cross-match facility and early 
surgery are logistical factors which would improve the deceased donor 
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Name:    Age:  Sex:  Blood Group: 
 
Address:      Occupation: 
 
 
Income:  Social Status:  Wt:  Ht:   BMI: 
 






Creatinine:    eGFR   NKD 
 
Sodium  Potassium  Bicarbonate   Chloride   
 
LFT  Serum Billurubin(T) D Alb Glob  SGOT 
SGPT  SAP 
 
Urine Routine:  24hrs urine Protein  Urine C/S 
 




BT  CT  FT4  TSH 
 
Calcium   Phosphorus   Uric acid 
 
Serology: HBsAg Anti Hcv   HIV  CMV 
 
ECHO   Gynecology   Dermatology 
 
Dental   ENT    MGE 
 




Cross matching    USG 
Renal Biopsy    Chest X-ray   ECG 
On MHD Duration:   Weekly: 
H/o Blood Transfusion 
H/o access problem   Doppler iliac vessels: 
Date of Reg:   Date of Transplant:  Waiting time: 
Intra op events: 
Post op events: 
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Urine 
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Post Transplant Ultra sound / Doppler 
 
Tacro level      HB  PCV 
Platelets 
 










 DONOR PROFORMA 
 
Name:    Age:  Sex:   
 
Address:      Occupation: 
 
       Blood Group: 
 
 
Income:  Social Status:  Wt:  Ht:   BMI: 
 
Cause of Brain death: 
 




Creatinine:     
 
Sodium  Potassium  Bicarbonate   Chloride   
 
LFT  Serum Billurubin(T) D Alb Glob  SGOT 
SGPT  SAP 
 
HB  PCV  Platelets  PT  aPTT  INR 
 













DOS: Donor Nephrectomy: 

























































































































































































1 Kondiaraj 32 M O+ 5.10% 25.10.08 23.1 1.7 1.6 1.4 CGN YES NO 36 N 
2 Balaraman 32 M B+  5.10% 21.11.08 22.2 1.6 1.2 1.1 CGN YES NO 12 LVH 
3 Bala krishnan 31 M B+  5.10% 14.1.09 20.2 8.7 1.4 1.3 CGN YES NO 6 LVH 
4 Lilly Theresa  29 M B+  5.10% 28.1.09 32.2 2 1.3 1.2 CGN YES NO 6 N 
5 SasiKumar 29 M A+ 5.10% 4.2.09 18.7 1 1.2 -- CGN YES NO 28 N 
6 Baskar  38 M AB+ 5.10% 9.3.09 17.9 2.3 1.6 1.7 CGN YES NO 3 LVH 
7 Dasan  48 M O+ 5.10% 14.3.09 25.6 4.2 4 1.6 ADPKD YES NO 24 N 
8 Sakthivel 27 M B+  5.10% 26.4.09 25.4 13.1 -- -- CGN YES NO 30 N 
9 Renuka  34 M B+  5.10% 11.5.09 22.2 1.4 1 0.9 IgAN YES NO 48 N 
10 Xavier  43 M O+ 5.10% 21.6.09 25.8 -- -- -- CGN YES NO 24 N 
11 GopiKrishnan  40 M B+  5.10% 8.8.09 22.1 3.1 1.2 1.3 FSGS YES NO 3 EF40%
12 Subramani  48 M O+ 5.10% 15.10.09 19.5 0.9 0.9 0.8 CGN YES NO 48 N 
13 JayaKumar 30 M B- 5.10% 27.10.09 20.8 2.1 1.2 1.1 CGN YES NO 1 N 
14 Eswaran 31 M B+  5.10% 13.11.09 28.1 7.3 5.6 -- CGN YES NO 12 N 
15 Prema 35 F A- 5.10% 4.12.09 31.2 7.4 1 1.2 CGN YES NO 24 LVH 
16 Revathy 24 F O+ 5.10% 12.12.09 17.6 1.2 1.3 1.1 CGN YES NO 12 LVH 
17 Devaraj 46 M O+ 5.10% 16.12.09 18.1 1.3 1.2 1.1 CGN YES NO 12 LVH 
18 Palani 37 M O+ 5.10% 27.12.09 19.3 1.6 1.4 1.2 CGN YES NO 24 LVH 
19 Elawarasan 22 M AB+ 5.10% 20.2.10 17.4 1 0.9 -- CGN YES NO 24 N 
20 Riyaz ali 25 M B+  5.10% 27.2.10 18.9 0.9 0.8 0.8 CGN YES NO 12 N 
21  Dass Prakash  31 M  B+  5.10% 19.3.10 26.6 1.6 1.2 1 CGN YES NO 6 N 
22 Rajan 36 M B+  5.10% 6.4.10 22.3 5.3 -- -- CGN YES NO 3 N 
23 Devi    29 F O+ 5.10% 11.4.10 17.3 1.2 0.9 0.9 CGN YES NO 1 LVH 





























































































































1 NIL NIL 10 NEG N Radhakrishnan 49 M O+ NO NO LEFT 10 
2 NIL NIL 8 NEG N Gnanaprakasem 26 M B+ NO NO LEFT 8 
3 NIL HD-3 10 NEG N  Premkumar  48 M B+ NO NO LEFT 12 
4 Bleeding NIL 3 NEG N Jeevarathinam,  56 F B+ NO NO LEFT 12 
5 NIL NIL 16.3 NEG N  Suganya   15 F A+ NO NO LEFT 3 
6 NIL ACC.HT 10 NEG N  Asha  20 F AB+ NO NO LEFT 10 
7 NIL SEPSIS 2.9 HBV+ N  Jeyanthi Reddy 39 M O+ NO NO LEFT 10 
8 Mottling Nephrectomy 3.1 HCV+ N  Chandru  27 M B+ NO NO LEFT 10 
9 Venous leak NIL 14.2 NEG N  Dharani  19 F B+ NO NO LEFT 7 
10 EIA 
Rt leg 
ischemia   NEG N Sivaprakasam 42 M O+ NO NO LEFT 12 
11 Hilum anas   Hypotension 18 NEG N John rayan 57 m B+ NO NO LEFT 10 
12 NIL NIL 8 NEG N Vinoth Kumar  28 M O+ NO NO LEFT 11 
13 NIL Pancreatitis 11 NEG N Iyyappan 28 M B+ NO NO RIGHT 10 
14 Hypotension persistent DT 13 NEG N Loganathan  23 M B+ NO NO RIGHT 12 
15 Hypotension Ionotropes 3.8 NEG N JaiAnand  18 F A+ NO NO LEFT 12 
16 NIL SEPSIS/ARDS 15 NEG N Palanivel  24 M O+ NO NO RIGHT 11 
17 NIL NIL 10.3 NEG N chandran 56 M O+ NO NO LEFT 11 
18 NIL NIL 15.2 NEG N Jayabharthi 15 F O+ NO NO LEFT 3 
19 NIL NIL 9 NEG N Vijay 12 M AB+ NO NO LEFT 5 
20 NIL NIL 12 NEG N Venkatasen  29 M O+ NO NO RIGHT 5.5 
21 NIL NIL 10.9 NEG N Kuppan 45 M B+ NO NO RIGHT 10 
22 NIL 
Fungal 
sinusitis   NEG N Malliga 34 F B+ NO NO RIGHT 8 
23 NIL Stitch abscess 9.3 NEG N Lakshmi  45 F O+ NO NO RIGHT 9 





























































































































RA/CUFF RTA N DIED(18/1/10) CAN HTK T/M/P I Cr.1 wk : Creatinine value at 1 week Post Operation 
2 NIL RTA N DIED(20/1/10) NIL HTK T/M/P I 
Cr.1 mon 
: 
Creatinine value at 1 month Post 
Operation 
3 3RA RTA DGF ALIVE NIL HTK T/M/P I 
Cr.6 mon 
: 
Creatinine value at 6 months Post 
Operation
4 NIL RTA N ALIVE NIL HTK T/M/P I 
Intra OP 
: Intra Operative events 
5 2RA RTA N DIED(9/4/9) NIL HTK T/M/P I Post OP : Post operative events 
6 NIL RTA N DIED(15/6/9) HUS HTK T/M/P I 
Tacro 
level : Tacrolimus through level 
7 NIL RTA DGF DIED(30/4/9) NIL HTK T/M/P I CIT : Cold Ischemic Time 
8 NIL RTA DGF ALIVE NIL HTK T/M/P I Tx - I/II : First or Second Transplant
9 NIL RTA N ALIVE NIL HTK T/M/P I CGN : Chronic Glomeulo Nephritis 
10 2 RA RTA DGF DIED(22/6/9) NIL HTK T/M/P I ADPKD : 
Autonomal Dominant Polycyotic Kidney 
disease 
11 NIL RTA DGF ALIVE NIL HTK T/M/P I IgAN : IgA Nephropathy 
12 NIL RTA N ALIVE NIL HTK T/M/P I LVH : Left Ventricular Hypertrophy 
13 NIL RTA N ALIVE NIL HTK T/M/P I RTA : Road Traffic Accident 




AHR HTK T/M/P II 
T/M/P : Tacrolimus, Mycophenolate mofetil and  
Prednisolone 
15 2 RA 
Fall from 
ht DGF ALIVE NIL HTK T/M/P I 
16 NIL RTA N ALIVE NIL HTK T/M/P I 
17 NIL RTA N ALIVE NIL HTK T/M/P I 
18 NIL RTA N ALIVE NIL HTK T/M/P I 
19 NIL RTA N ALIVE NIL HTK T/M/P I 
 20 2 RA RTA N ALIVE NIL HTK T/M/P I 
21 NIL RTA N ALIVE NIL HTK T/M/P I 
22 NIL RTA DGF DIED(16/4/10) NIL HTK T/M/P I 
23 NIL RTA N ALIVE NIL HTK T/M/P I 
24 NIL 
Fall from 
ht DGF ALIVE NIL HTK T/M/P I 
 
 
 
 
